Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. on behalf of investors who sold or held shares during a specified period, alleging misleading statements related to a secondary stock offering and an acquisition by AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit covers individuals or entities that sold or held Cerevel common stock from October 11, 2023, to August 1, 2024, and those entitled to vote on the merger with AbbVie [1] - Allegations include that Bain Capital and Pfizer orchestrated a secondary stock offering to allow Bain to acquire shares at a discounted price before AbbVie’s acquisition announcement [5] - The acquisition by AbbVie was announced at $45 per share, nearly double the offering price, resulting in Bain Capital receiving over $120 million in windfall profits [5] Group 2: Legal Representation - Investors may join the class action without any out-of-pocket fees through a contingency fee arrangement [2] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - A lead plaintiff must be appointed by June 3, 2025, to represent the interests of the class members [1][3]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for violations of federal securities laws, impacting investors who sold shares during a specified period, held shares on a record date, or sold shares during a significant transaction involving Bain Capital [1][2][3] Group 1: Lawsuit Details - The lawsuit includes three classes of investors: those who sold shares between October 11, 2023, and August 1, 2024, those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1] - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted material facts about AbbVie's interest in acquiring Cerevel, which artificially deflated the stock price [2] - Following the October Offering, Cerevel announced a merger with AbbVie at $45 per share, resulting in significant financial gains for Bain Capital, which acquired shares at a depressed price [3] Group 2: Financial Impact - Bain Capital reportedly received over $120 million from the shares acquired during the October Offering due to the subsequent merger announcement [3] - Investors who suffered losses exceeding $100,000 in Cerevel's securities are encouraged to participate in the lawsuit [4]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for alleged violations of securities laws, specifically related to misleading statements made during a secondary stock offering and a proxy statement regarding a merger with AbbVie Inc. [1][5] Group 1: Lawsuit Details - The lawsuit targets investors who purchased shares between October 11, 2023, and August 1, 2024, or held shares as of January 8, 2024, and were entitled to vote on the merger [2] - The class has not yet been certified, meaning potential class members are not currently represented by an attorney [4] Group 2: Allegations Against Cerevel - Cerevel is accused of making false and misleading statements regarding its secondary stock offering on October 16, 2023, and its proxy statement on January 18, 2024, related to AbbVie's acquisition at $45 per share [5] - The secondary stock offering was allegedly organized by Bain and Pfizer to increase Bain's investment at a discounted price, anticipating AbbVie's undisclosed acquisition plan [5] - The acquisition plan was publicly announced just 51 days after the secondary offering, at a price nearly double the offering price, leading to investor damages when the truth emerged [5]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. for allegedly misleading investors regarding the acquisition interest from AbbVie, which impacted the stock price during the class period from October 11, 2023, to August 1, 2024 [1][3]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the District of Delaware on behalf of all individuals and entities who purchased Cerevel securities during the specified class period [1]. - Investors have until June 3, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Cerevel - The complaint alleges that Cerevel's offering documents and public statements omitted material facts about AbbVie's interest in acquiring Cerevel at a price significantly higher than the $22.81 per share offering price, which artificially deflated the stock price until the merger announcement [3]. - It is claimed that Bain, Cerevel's controlling shareholder, acquired shares at an artificially depressed price while possessing nonpublic information about AbbVie's interest [3]. - On December 6, 2023, Cerevel announced that AbbVie agreed to acquire the company for $45 per share, resulting in Bain receiving over $120 million in windfall profits from shares acquired at the lower offering price [3]. Impact on Investors - The action seeks to recover damages for investors who held shares as of the January 8, 2024, record date and were harmed by the allegedly false and misleading statements in Cerevel's January 18, 2024, proxy statement [4]. - The proxy statement is alleged to have misled investors regarding the true nature and timing of AbbVie's interest in Cerevel [4].

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, alleging violations of federal securities laws related to the merger with AbbVie Inc. [1][2] Group 1: Class Definition - The lawsuit seeks damages for individuals and entities that sold or disposed of Cerevel's common stock from October 11, 2023, to August 1, 2024, and were harmed by the defendants' violations of Section 10(b) of the Securities Exchange Act of 1934 [2] - It also includes those who held shares as of January 8, 2024, and were entitled to vote on the merger, as well as those who sold shares contemporaneously with Bain's purchase on or about October 16, 2023, alleging harm from Bain's violations of Section 20A of the Exchange Act [2] Group 2: Case Details - The Complaint alleges that Cerevel's Offering documents omitted material facts regarding AbbVie's interest in acquiring Cerevel at a price significantly higher than the $22.81 per share Offering price, which artificially deflated Cerevel's stock price until the merger announcement [3] - It is claimed that Bain acquired shares at an artificially depressed price while possessing material nonpublic information about AbbVie's interest, leading to a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share [3] Group 3: Proxy Statement Allegations - The lawsuit also seeks damages for investors who held shares as of the January 8, 2024, Record Date, alleging that Cerevel's January 18, 2024, Proxy statement contained false and misleading statements regarding AbbVie's interest in the company [4] Group 4: Next Steps - Investors who suffered losses in Cerevel have until June 3, 2025, to request to be appointed as lead plaintiff in the class action lawsuit [5]

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for allegedly misleading investors regarding a secondary stock offering and the subsequent merger with AbbVie Inc. [1][2] Group 1: Allegations and Impact - The lawsuit claims that Cerevel's secondary offering documents omitted crucial information about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which led to an artificially deflated stock price until the merger announcement [2] - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at this depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding $120 million when AbbVie announced the acquisition at $45 per share [2] - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3] Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, to represent the class in the litigation [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 3: Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - The Schall Law Firm is investigating Cerevel Therapeutics Holdings, Inc. for potential violations of securities laws and breaches of fiduciary duty by its directors and management [1][2]. Group 1: Investigation Details - The investigation centers on whether Cerevel issued false or misleading statements and failed to disclose important information to investors [2]. - Cerevel was acquired by AbbVie Inc. on August 1, 2024, at a price of $45 per share [2]. Group 2: Legal Representation - The Schall Law Firm offers free consultations to shareholders who may have suffered losses and encourages them to discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. and AbbVie, Inc., raising concerns about the fairness of the transaction and the potential conflicts of interest among Cerevel's board of directors [4][5]. Group 1: Merger Details - On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie for $45.00 per share in cash, valuing the company at approximately $8.7 billion [8]. - The transaction has been approved by the boards of directors of both companies and is expected to close in mid-2024 [8]. Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [5]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options related to the merger [6].

Core Viewpoint - Cerevel Therapeutics is set to be acquired by AbbVie for $45.00 per share, valuing the company at approximately $8.7 billion, with the transaction expected to close in mid-2024 [1] Group 1: Acquisition Details - AbbVie will acquire all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash [1] - The total equity value of the transaction is approximately $8.7 billion [1] - The boards of directors of both companies have approved the transaction [1] Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating the acquisition, alleging that Cerevel's board was conflicted and engaged in an unfair process [2][5] - Current shareholders of Cerevel are encouraged to submit their information to understand their rights regarding the transaction [2][3]

Core Viewpoint - The Schall Law Firm is investigating potential breaches of fiduciary duty by the board of Cerevel Therapeutics Holdings, Inc. towards its shareholders [1][3]. Group 1: Investigation Details - The investigation aims to determine if the Cerevel board has violated its fiduciary responsibilities to shareholders [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2][3]. Group 2: Contact Information - Investors can contact Brian Schall of the Schall Law Firm for discussions regarding their rights without any charge [4][6].